FATE 241220 3.00P (FATE241220P3000) Stock Options, News & Quotes

US OptionsDetailed Quotes

FATE241220P3000

Watchlist

0.35
0.000.00%

15min DelayClose Dec 3 16:00 ET

0.00High0.00Low

Intraday

5D
Daily

News

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire16:01 ET
Express News | Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Reuters16:01 ET
Fate Therapeutics Taps Bob Valamehr to Be CEO
WSJNov 29 13:38 ET
Fate Therapeutics Announces Leadership Transition; Scott Wolchko To Retire As President And CEO, Bob Valamehr To Become President And CEO January 1, 2025
BenzingaNov 29 13:06 ET
Express News | Fate Therapeutics Inc - Bob Valamehr to Become President and CEO Jan 1, 2025
ReutersNov 29 13:05 ET
Express News | Fate Therapeutics Inc - Scott Wolchko to Retire as President and CEO Dec 31, 2024
ReutersNov 29 13:05 ET

Comments

Comment allez vous

Nov 26 08:11

Roche 😙

$Fate Therapeutics (FATE.US)$ Roche buying Fate too?

liang wang199

Nov 18 11:21

There will be a big rise soon.

Jaguar8

Nov 18 09:01

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Presents 6-Month Follow-Up Data On First Patient Treated In Phase 1 Autoimmunity Study With Fludarabine-Free Conditioning And FT819 Off-The-Shelf, 1XX CAR T-Cell Product Candidate At ACR Convergence
27-year-old African American-Asian Woman with Active Lupus Nephritis Achieved DORIS Clinical Remission; Patient Remains On-study, in Clinical Remission, and Free of All Immunosuppressive Therapies
Patient Treated with Fludarabine-free Conditioning a...

Stock_Drift

Nov 9 13:03

$Fate Therapeutics (FATE.US)$

Jaguar8

Nov 9 12:31

NEWS

$Fate Therapeutics (FATE.US)$
Fate Therapeutics Highlights Cancer-selective, HER2-Targeting Profile of FT825 / ONO-8250 CAR T-cell Product Candidate for Treatment of Advanced Solid Tumors at 2024 SITC Annual Meeting
Fate Therapeutics (NASDAQ: FATE) presented initial clinical and preclinical data for FT825/ONO-8250, a CAR T-cell therapy targeting HER2 in advanced solid tumors. The Phase 1 study's first low-dose cohort of three heavily pre-treated patients showed favorable safety outcomes with ...